Mohammad Mehdi Mahboobian

Dr. Mohammad Mehdi Mahboobian


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
MMMohammad Mehdi Mahboobian
Mohammad Mehdi Mahboobian
ASAli Seyfoddin
Ali Seyfoddin
RAReza Aboofazeli
Reza Aboofazeli
SFSeyed Mohsen Foroutan
Seyed Mohsen Foroutan
Ilva RupenthalIlva Rupenthal
Ilva Rupenthal
The aim of this study was to investigate the corneal penetration of brinzolamide nanoemulsions and evaluate their in vitro and ex vivo irritancy potential. Twelve brinzolamide nanoemulsions were prepared by the spontaneous emulsification method and ex vivo permeability studies were conducted using excised bovine corneas fixed onto Franz diffusion cells. To confirm the safety of the formulations for ophthalmic use, preparations were examined for potential ocular irritancy using a cell viability assay on retinal cells, the hen’s egg test-chorioallantoic membrane (HET-CAM) and the bovine corneal opacity-permeability (BCOP) test. Seven brinzolamide nanoemulsions exhibited superior penetration across isolated bovine cornea compared to the marketed brinzolamide suspension. The half maximal inhibitory concentration (IC50) values of various surfactants and oils determined using the sulforhodamine B cell viability assay on retinal cells showed that Transcutol P, Cremophor RH40 and Triacetin were the least toxic excipients and may be safely used in the eye at various concentrations. HET-CAM and BCOP tests revealed that NE6B and NE4C did not results in any irritation and were thus considered safe for ocular use. Our finding suggest that optimized nanoemulsions can be a safe and effective vehicle for ocular delivery of brinzolamide.

13 March 2021 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
MBMasoumeh Bayanati
Masoumeh Bayanati
AKAbolfazl Ghafouri Khosroshahi
Abolfazl Ghafouri Khosroshahi
MAMaryam Alvandi
Maryam Alvandi
MMMohammad Mehdi Mahboobian
Mohammad Mehdi Mahboobian
In this study, a thermosensitive in situ gel nanoemulsion was formulated by a low energy method for intranasal delivery of temozolomide to bypass the blood-brain barrier and optimize chemotherapy for glioblastoma. Various amounts of Labrasol, Transcutol®P, and Triacetin were chosen as nanoemulsion components based on the solubility and the partial pseudoternary phase diagrams studies. Poloxamer derivatives added to the selected nanoemulsion and gelling temperature optimized. The prepared in situ gel nanoemulsion containing temozolomide showed a mean droplet size of , a polydispersity index value of , and desirable pH and viscosity. In vitro release studies revealed that both nanoemulsion and in situ gel preparation have sustained release pattern in comparison to the control solution. Visual evaluation and droplet size and polydispersity index measurements showed both nanoemulsion and in situ gel nanoemulsion were stable during heating-cooling and freeze-thaw cycles and also centrifugation. Mucoadhesion percentage of in situ gel nanoemulsion was regarding ex vivo studies, which had a significant rise in comparison to control solution and nanoemulsion. Permeation across the nasal mucosa was 1.43- and 1.52-fold higher than the control solution for nanoemulsion and in situ nanoemulsion, respectively. Gamma scintigraphy study showed brain accumulation of developed nanoemulsion formulations. Our studies demonstrated optimized formulation has suitable physicochemical properties, desirable release profile, enhanced permeation across the nasal mucosa, and prolonged resistance time at the nasal mucosa. Therefore, in situ gel nanoemulsion would be an effective novel nasal delivery system for the treatment of glioblastoma.

4 March 2021 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
ZSZahra Saghafi
Zahra Saghafi
MMMojdeh Mohammadi
Mojdeh Mohammadi
MMMohammad Mehdi Mahboobian
Mohammad Mehdi Mahboobian
KDKatayoun Derakhshandeh
Katayoun Derakhshandeh
The main scope of the present investigation was to improve the bioavailability of perphenazine (PPZ) by incorporating it into the nanostructured lipid carriers (NLCs).As a result of lipophilic natu...

11 February 2021 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
SKSeyedeh Negin Kassaee
Seyedeh Negin Kassaee
MMMohammad Mehdi Mahboobian
Mohammad Mehdi Mahboobian

25 May 2021 in Current Eye Research
Verified
Journal Article
Closed access
MMMojdeh Mohammadi
Mojdeh Mohammadi
ZEZohreh Elahimehr
Zohreh Elahimehr
MMMohammad Mehdi Mahboobian
Mohammad Mehdi Mahboobian
Objective: The main goal of the present work was to develop and evaluate nanoemulsions (NEs) containing acyclovir (ACV) for ophthalmic drug delivery. Method: Firstly, component screening was performed by determining ACV solubility in various oils, surfactants, and co-surfactants. Different NE formulations were developed based on pseudo-ternary phase diagrams, and physicochemical assets were evaluated. Selected formulations were subjected to the drug release efficacy, stability studies, and ex-vivo trans-corneal permeation test. The safety of NEs was investigated by the modified Draize test and hen’s egg test-chorioallantoic membrane (HET-CAM). Results: Based on the solubility studies, Tween 20, Triacetin, and Tramsectol®P were chosen to prepare NE formulations. Developed NEs showed desirable physiochemical properties, including a droplet size of less than 15 nm. Selected formulations (F1 and F2) exhibited a sustained drug release pattern compared to the control group (P < .001). ACV penetration from F1 and F2 to the excised bovine cornea was 2.85 and 2.9-fold more than the control, respectively. Furthermore, HET-CAM and modified Draize test confirmed that F1 and F2 were safe for ocular administration. Conclusion: Present investigation revealed that ACV-loaded NEs could be effective, and safe platform for ophthalmic delivery of ACV.

18 December 2020 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PMParnian Mohammadi
Parnian Mohammadi
RMReza Mahjub
Reza Mahjub
MMMojdeh Mohammadi
Mojdeh Mohammadi
KDKatayoun Derakhshandeh
Katayoun Derakhshandeh
AGAli Ghaleiha
Ali Ghaleiha
MMMohammad Mehdi Mahboobian
Mohammad Mehdi Mahboobian
Perphenazine (PPZ) is a typical antipsychotic that is mainly administrated for the treatment of schizophrenia. Due to its highly lipophilic nature and extensive hepatic first-pass metabolism, its o...